/

/

/

Combined Oral, Subcutaneous, and Intravenous Administration of Therapeutic Agents to Marmoset for Treating Wasting Marmoset Syndrome (WMS)

JoVE Journal
Medicine

This content is Free Access.

JoVE Journal Medicine

Combined Oral, Subcutaneous, and Intravenous Administration of Therapeutic Agents to Marmoset for Treating Wasting Marmoset Syndrome (WMS)

Combined Oral, Subcutaneous, and Intravenous Administration of Therapeutic Agents to Marmoset for Treating Wasting Marmoset Syndrome (WMS)

22 Views

•

01:50 min

•

July 12, 2024

DOI:

10.3791/201991-v

DOI:

10.3791/201991-v

•

01:50 min

July 12, 2024

•

0 Views

Chie Sano¹, Ken Suenaga¹, Yuko Shigeno¹, Kimie Niimi¹

¹Support Unit for Animal Resources Development, Research Resources Division,RIKEN Center for Brain Science

Explore More Videos

Wasting Marmoset Syndrome WMS Common Marmoset Callithrix Jacchus Tranexamic Acid Supportive Measures Amino Acid Formulation Ringer’s Lactate Vitamin Formulation Iron Formulation Intravenous Administration Subcutaneous Administration Oral Administration Treatment Modification

Read Article